Skip to main content
Clinical Trials/NCT03535714
NCT03535714
Unknown
Not Applicable

MANTR-a: Evaluation of a Therapeutic Intervention for Adolescents and Young Adults With Anorexia Nervosa

Medical University of Vienna1 site in 1 country100 target enrollmentApril 25, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anorexia Nervosa
Sponsor
Medical University of Vienna
Enrollment
100
Locations
1
Primary Endpoint
Improvement of eating disorder symptomatology based on professional's rating
Last Updated
5 years ago

Overview

Brief Summary

The aim of this study is to test effectiveness of a new treatment program for adolescents and young adults within the age of 14-21 suffering from AN (MANTR-a) compared to treatment as usual (TAU).

Detailed Description

Anorexia nervosa (AN) is a serious mental illness which leads untreated to aggravation of symptomatology and chronification. Among all mental illnesses, AN has the highest mortality rate, which is about 5.1 per 1000 people per year. High drop-out rates (up to 40%) or small treatment motivation constrains treatment success. Since the onset of AN is mainly in adolescence, it is important to start with therapy as early as possible and establish an effective single-setting treatment program for this age group to prevent chronification. MANTR-a (Maudsley model of anorexia nervosa treatment for adolescents) is an innovative, theory-based, tailored treatment program which combines a cognitive behavioural approach with motivational interviewing. The main focus of the treatment program is the transformation maintaining factors of AN, like personality aspects, pro-anorexic beliefs, emotion regulation strategies, thinking styles and obstructive behaviour from caregivers. The aim of this study is the examination ot the effectiveness of the MANTR-a treatment program for adolescents and young adults. Therefore we compare MANTR-a (intervention group) with treatment as usual (control group). Assessments will be conducted before treatment (T0, baseline), after six months (T1), after 12 months (T2) and after 18 months (T3, follow-up) via questionnaires, interviews and neuropsychological measurements. Process evaluation takes place after every session. Each group consists of female adolescents and young adults within the age of 14-21 suffering from AN (ICD-10: F50.0, F50.1), resulting in an overall sample size of 100. The long-term goal of the study is to provide an evidence-based outpatient treatment for children and adolescents with AN in order to prevent a chronic course of the disease.

Registry
clinicaltrials.gov
Start Date
April 25, 2018
End Date
August 31, 2022
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Andreas Karwautz

Univ. Prof. Dr.

Medical University of Vienna

Eligibility Criteria

Inclusion Criteria

  • ICD-10 diagnosis of anorexia nervosa (F50.0) or atypical anorexia nervosa (F50.1).

Exclusion Criteria

  • life-threatening AN requiring immediate inpatient treatment as defined by NICE (2017)
  • insufficient cognitive ability
  • insufficient knowledge of German language to understand the treatment
  • severe mental or physical illness that needs treatment on its own (e.g. psychosis)
  • substance abuse
  • pregnancy

Outcomes

Primary Outcomes

Improvement of eating disorder symptomatology based on professional's rating

Time Frame: 12 months

Professionals use a structured clinical interview ("Eating Disorder Examination - EDE") to rate severity of eating disorder symptomatology

Increase of BMI

Time Frame: 12 months

Weight and height will be assessed and combined to report BMI in kg/m\^2

Improvement of eating disorder symptomatology based on patient's self-rating

Time Frame: 12 months

"Eating Disorder Inventory-2 (EDI-2)" is used to assess eating disorder symptomatology from a patients's view

Secondary Outcomes

  • Increase of BMI(6 months, 18 months)
  • Improvement of eating disorder symptomatology based on patient's self-rating(6 months, 18 months)
  • Group differences: improvement of eating disorder symptomatology based on patient's self-rating(6 months, 12 months, 18 months)
  • Reduction of depression(6 months, 12 months, 18 months)
  • Quality of life (group differences, improvement over time)(6 months, 12 months, 18 months)
  • Improvement of comorbid symptomatology based on professional's rating(6 months, 12 months, 18 months)
  • Increase of central coherence(12 months)
  • Increase of emotion recognition(12 months)
  • Influence of motivation of change(12 months)
  • Influence of treatment contentment(6 months, 12 months)
  • Improvement of eating disorder symptomatology based on professional's rating(6 months, 18 months)
  • Reduction of obsessive-compulsive symptomatology(6 months, 12 months, 18 months)
  • Group differences: improvement of eating disorder symptomatology based on professional's rating(6 months, 12 months, 18 months)
  • Group differences: increase of BMI(6 months, 12 months, 18 months)
  • Reduction of anxiety(6 months, 12 months, 18 months)
  • Increase of cognitive flexibility(12 months)
  • Influence of therapeutic relationship(6 months, 12 months)
  • Changes in personality(12 months)

Study Sites (1)

Loading locations...

Similar Trials